Follistatin Antibody (FST/4281) [DyLight 488]

• Reactivity: Hu
• Applications: ELISA, IHC
• Clone: FST/4281
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: DyLight 488

Follistatin Antibody (FST/4281) [DyLight 488] Summary

• Immunogen: Raised to human Follistatin (Fst) 288 and recognizes both human Fst 288 and 315 (Uniprot: P19883)
• Localization: Secreted.
• Specificity: Follistatin is a single-chain glycosylated protein that inhibits follicle stimulating hormone (FSH) release. Alternative splicing of Follistatin mRNA yields two isoforms, FS315 and FS288. FS288 is the main cell-surface form and binds to surface heparin sulphate proteoglycans. FST/4281 is a clone raised against recombinant Fst 288, and is used in combination, commonly as the capture, with antibody FST/4282 in a two site ELISA for the detection of Follistatin.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: FST
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Immunohistochemistry-Paraffin
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein A or G purified

Notes

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Alternate Names for Follistatin Antibody (FST/4281) [DyLight 488]

• follistatin isoform FST317
• Follistatin
• FS
• FSActivin-binding protein
• FST

Background

FST, also known as Follistatin, has a 344 amino acid long isoform that is 38 kDa and a short 317 amino acid that is 35 kDa, functions as an activin antagonist binding directly to it and inhibits the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH). Studies of this protein are being performed in relation to polycystic ovary syndrome, pituitary adenoma, insulin resistance, Down syndrome, plasmacytoma, lymphocytic leukemia, pituitary tumor infertility, endometrial carcinoma, teratocarcinoma, azoospermia, meningitis, hepatocellular carcinoma, ovarian carcinoma, liver disease, endometriosis, prostate carcinoma, prostatitis, ovarian cancer, and adenoma. This protein has been also shown to have interactions with ANG, DIP2A, BMP4, FN1, and TXN in signal transduction activin A signaling regulation and TGF-beta signaling pathways.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: FST